SCHEMBL4248549

SCHEMBL4248549

O=C(O)c1cc(-c2cccc(Cl)c2)nc2ncccc12

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.55
KMO O15229 2/20 0.53
DHODH Q02127 5/20 0.51
KMT2A Q03164 3/20 0.50
MEN1 O00255 2/20 0.50
HPGD P15428 2/20 0.50
PDE4A P27815 1/20 0.49
PDE4C Q08493 1/20 0.49
PDE4D Q08499 1/20 0.49
AKR1C3 P42330 1/20 0.49
AKR1C2 P52895 1/20 0.49
AKR1C1 Q04828 1/20 0.49
KDM4E B2RXH2 2/20 0.49
LMNA P02545 2/20 0.49
SMN1; SMN2 Q16637 1/20 0.49
PDE10A Q9Y233 1/20 0.49
NPC1 O15118 1/20 0.48
RAB9A P51151 1/20 0.48
GFER P55789 1/20 0.48
HTT P42858 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4244305 0.86 KDM4E (0.65) ALDH1A1DHODHAKR1C3AKR1C2AKR1C1
SCHEMBL4249905 0.81 KDM4E (0.56) ALDH1A1DHODHKMT2AMEN1HPGD
SCHEMBL1905456 0.81 SMN1; SMN2 (0.75) ALDH1A1DHODHKMT2AMEN1HPGD
SCHEMBL246458 0.81 ABCG2 (0.48) ALDH1A1KMOPDE4APDE4CPDE4D
SCHEMBL13460462 0.79 DHODH (0.56) ALDH1A1DHODHHPGDKDM4ELMNA
SCHEMBL13460561 0.79 DHODH (0.59) ALDH1A1DHODHHPGDKDM4ELMNA
SCHEMBL4251930 0.79 SYK (0.48) ALDH1A1KMO
SCHEMBL4248498 0.77 ALDH1A1 (0.54) ALDH1A1KMODHODHKMT2AMEN1
SCHEMBL4249919 0.77 DHODH (0.60) DHODHKDM4ELMNASMN1; SMN2PDE10A
SCHEMBL4245179 0.77 TP53 (0.72) ALDH1A1DHODHKMT2AMEN1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090042928-A1 Modulators of muscarinic receptors VERTEX PHARMACEUTICALS INCORPORATED 2009-02-12 US disclosed
US-20090042928-A1 Modulators of muscarinic receptors VERTEX PHARMACEUTICALS INCORPORATED 2009-02-12 US disclosed
US-20090042928-A1 Modulators of muscarinic receptors VERTEX PHARMACEUTICALS INCORPORATED 2009-02-12 US disclosed
US-7446112-B2 Modulators of muscarinic receptors VERTEX PHARMACEUTICALS INCORPORATED (US) 2008-11-04 US disclosed
US-7446112-B2 Modulators of muscarinic receptors VERTEX PHARMACEUTICALS INCORPORATED (US) 2008-11-04 US disclosed
US-7446112-B2 Modulators of muscarinic receptors VERTEX PHARMACEUTICALS INCORPORATED (US) 2008-11-04 US disclosed
EP-1709045-A1 NAPHTHYRIDINE DERIVATIVES AND THEIR USE AS MODULATORS OF MUSCARINIC RECEPTORS Vertex Pharmaceuticals Incorporated (US) 2006-10-11 EP disclosed
US-20050171141-A1 Modulators of muscarinic receptors VERTEX PHARMACEUTICALS INCORPORATED 2005-08-04 US disclosed
WO-2005056552-A1 NAPHTHYRIDINE DERIVATIVES AND THEIR USE AS MODULATORS OF MUSCARINIC RECEPTORS VERTEX PHARMACEUTICALS INCORPORATED (US) 2005-06-23 WO disclosed
WO-2005056552-A1 NAPHTHYRIDINE DERIVATIVES AND THEIR USE AS MODULATORS OF MUSCARINIC RECEPTORS VERTEX PHARMACEUTICALS INCORPORATED (US) 2005-06-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050171141-A1 Modulators of muscarinic receptors CHRM3, CHRM2, CHRM4 ALDH1A1 2677/4885KMO 1191/4885DHODH 3465/4885
US-20090042928-A1 Modulators of muscarinic receptors CHRM3, CHRM2, CHRM4 ALDH1A1 2677/4885KMO 1191/4885DHODH 3465/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.